These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 16928481)

  • 1. FDA perspective on clinical trial design for cardiovascular devices.
    Chen E; Sapirstein W; Ahn C; Swain J; Zuckerman B
    Ann Thorac Surg; 2006 Sep; 82(3):773-5. PubMed ID: 16928481
    [No Abstract]   [Full Text] [Related]  

  • 2. Progress versus precision: challenges in clinical trial design for left ventricular assist devices.
    Parides MK; Moskowitz AJ; Ascheim DD; Rose EA; Gelijns AC
    Ann Thorac Surg; 2006 Sep; 82(3):1140-6. PubMed ID: 16928569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prosthetic heart valves: Objective Performance Criteria versus randomized clinical trial.
    Grunkemeier GL; Jin R; Starr A
    Ann Thorac Surg; 2006 Sep; 82(3):776-80. PubMed ID: 16928482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial design issues in schizophrenic research.
    Casey DE
    J Clin Psychiatry; 2001; 62 Suppl 9():17-20; discussion 21-2. PubMed ID: 11379826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based medicine and drug-eluting stents.
    O'Dwyer J
    Med Device Technol; 2004 May; 15(4):34-7. PubMed ID: 15303564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overhauling clinical trials.
    Scott CT; Baker M
    Nat Biotechnol; 2007 Mar; 25(3):287-92. PubMed ID: 17344876
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA perspective on clinical trial design for femoropopliteal stent correction of peripheral vascular insufficiency cardiovascular devices.
    Goode J; Sapirstein W; Zuckerman B
    Catheter Cardiovasc Interv; 2007 May; 69(6):920-1. PubMed ID: 17455345
    [No Abstract]   [Full Text] [Related]  

  • 8. Designing trials for testing prosthetic cardiac valves: a Food and Drug Administration perspective.
    Sapirstein W
    Am Heart J; 2001 May; 141(5):861-3. PubMed ID: 11320379
    [No Abstract]   [Full Text] [Related]  

  • 9. Experience with reviewing Bayesian medical device trials.
    Pennello G; Thompson L
    J Biopharm Stat; 2008; 18(1):81-115. PubMed ID: 18161543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053
    [No Abstract]   [Full Text] [Related]  

  • 11. Food and Drug Administration's perspectives on pediatric cardiac assist devices.
    Chen EA; Patel-Raman SM; Berman MR; Zuckerman BD
    ASAIO J; 2008; 54(2):147-9. PubMed ID: 18356646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relocating abroad. FDA sends staff overseas to help monitor imports.
    Lee J
    Mod Healthc; 2011 Oct; 41(43):32. PubMed ID: 22111150
    [No Abstract]   [Full Text] [Related]  

  • 13. Overview of the 2011 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee Meeting on the Edwards SAPIEN™ transcatheter heart valve.
    Barbash IM; Waksman R
    Circulation; 2012 Jan; 125(3):550-5. PubMed ID: 22271848
    [No Abstract]   [Full Text] [Related]  

  • 14. VARC consensus report: the FDA perspective.
    Hillebrenner MG; Swain JA; Zuckerman B
    J Am Coll Cardiol; 2011 Jan; 57(3):270-1. PubMed ID: 21216554
    [No Abstract]   [Full Text] [Related]  

  • 15. Let the spin begin. Greater transparency urged for device trials.
    Becker C
    Mod Healthc; 2005 Mar; 35(11):33. PubMed ID: 15794228
    [No Abstract]   [Full Text] [Related]  

  • 16. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e302-4. PubMed ID: 15173052
    [No Abstract]   [Full Text] [Related]  

  • 17. Perspectives on the U.S. FDA Bioresearch Monitoring Program.
    Gamet JE
    Qual Assur; 1995 Mar; 4(1):12-9. PubMed ID: 8520859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microarray data--the US FDA, industry and academia.
    Hackett JL; Lesko LJ
    Nat Biotechnol; 2003 Jul; 21(7):742-3. PubMed ID: 12833089
    [No Abstract]   [Full Text] [Related]  

  • 19. International Conference on Harmonisation; choice of control group and related issues in clinical trials; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2001 May; 66(93):24390-1. PubMed ID: 12356096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanical devices and US Food and Drug Administration (FDA) approval.
    Reitz BA
    Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu; 2006; ():123-7. PubMed ID: 16638557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.